Zhaohui Ye

List of Publications by Year in Descending Order

82 papers	6,333 citations	38 h-index	79 g-index
82 ext. papers	6,871 ext. citations	7.2 avg, IF	5.24 L-index

#	Paper	IF	Citations
82	Convergence of human pluripotent stem cell, organoid, and genome editing technologies. *Experimental Biology and Medicine*, **2021**, 246, 861-875	3.7	2
81	Human-relevant preclinical in vitro models for studying hepatobiliary development and liver diseases using induced pluripotent stem cells. *Experimental Biology and Medicine*, **2019**, 244, 702-708	3.7	2
80	Targeting specificity of APOBEC-based cytosine base editor in human iPSCs determined by whole genome sequencing. *Nature Communications*, **2019**, 10, 5353	17.4	31
79	Biliary Atresia Relevant Human Induced Pluripotent Stem Cells Recapitulate Key Disease Features in a Dish. *Journal of Pediatric Gastroenterology and Nutrition*, **2019**, 68, 56-63	2.8	15
78	Transient c-Src Suppression During Endodermal Commitment of Human Induced Pluripotent Stem Cells Results in Abnormal Profibrotic Cholangiocyte-Like Cells. *Stem Cells*, **2019**, 37, 306-317	5.8	6
77	A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease. *Stem Cells Translational Medicine*, **2018**, 7, 87-97	6.9	42
76	Generation of human iPSCs from an essential thrombocythemia patient carrying a V501L mutation in the MPL gene. *Stem Cell Research*, **2017**, 18, 57-59	1.6	3
75	Derivation of a disease-specific human induced pluripotent stem cell line from a biliary atresia patient. *Stem Cell Research*, **2017**, 24, 25-28	1.6	3
74	A hypomorphic PIGA gene mutation causes severe defects in neuron development and susceptibility to complement-mediated toxicity in a human iPSC model. *PLoS ONE*, **2017**, 12, e0174074	3.7	11
73	Gene correction in patient-specific iPSCs for therapy development and disease modeling. *Human Genetics*, **2016**, 135, 1041-58	6.3	30
72	Generation, Characterization and Genetic Modification of Human iPSCs Containing Calr, MPL and JAK2 Mutations Found in MPN Patients. *Blood*, **2016**, 128, 3139-3139	2.2	1
71	Genome Editing in Human Pluripotent Stem Cells. *Pancreatic Islet Biology*, **2016**, 43-67	0.4	
70	A Method for Genome Editing in Human Pluripotent Stem Cells. *Cold Spring Harbor Protocols*, **2016**, 2016, pdb.prot090217	1.2	1
69	Genome Editing in Human Pluripotent Stem Cells. *Cold Spring Harbor Protocols*, **2016**, 2016, pdb.top086819	1.2	4
68	Efficient and Controlled Generation of 2D and 3D Bile Duct Tissue from Human Pluripotent Stem Cell-Derived Spheroids. *Stem Cell Reviews and Reports*, **2016**, 12, 500-8	6.4	27
67	Genome editing systems in novel therapies. *Discovery Medicine*, **2016**, 21, 57-64	2.5	6
66	Modified Ham test for atypical hemolytic uremic syndrome. *Blood*, **2015**, 125, 3637-46	2.2	76

65	Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation. *Stem Cells*, **2015**, 33, 1470-9	5.8	141
64	A facile method to establish human induced pluripotent stem cells from adult blood cells under feeder-free and xeno-free culture conditions: a clinically compliant approach. *Stem Cells Translational Medicine*, **2015**, 4, 320-32	6.9	56
63	Efficient and allele-specific genome editing of disease loci in human iPSCs. *Molecular Therapy*, **2015**, 23, 570-7	11.7	135
62	Covalent Modification of a Cysteine Residue in the XPB Subunit of the General Transcription Factor TFIIH Through Single Epoxide Cleavage of the Transcription Inhibitor Triptolide. *Angewandte Chemie*, **2015**, 127, 1879-1883	3.6	3
61	Covalent modification of a cysteine residue in the XPB subunit of the general transcription factor TFIIH through single epoxide cleavage of the transcription inhibitor triptolide. *Angewandte Chemie - International Edition*, **2015**, 54, 1859-63	16.4	49
60	The Roles of RUNX1 in Human Hematopoiesis and Megakaryopoiesis Revealed By Genome-Targeted Human iPSCs and an Improved Hematopoietic Differentiation Model. *Blood*, **2015**, 126, 1167-1167	2.2	
59	Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. *Stem Cells*, **2014**, 32, 269-78	5.8	29
58	Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. *Cell Stem Cell*, **2014**, 15, 12-3	18	274
57	Extensive ex vivo expansion of functional human erythroid precursors established from umbilical cord blood cells by defined factors. *Molecular Therapy*, **2014**, 22, 451-463	11.7	37
56	Early frameshift mutation in PIGA identified in a large XLID family without neonatal lethality. *Human Mutation*, **2014**, 35, 350-5	4.7	37
55	Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. *Science Translational Medicine*, **2014**, 6, 265ra168	17.5	341
54	Roles of reactive oxygen species in the fate of stem cells. *Antioxidants and Redox Signaling*, **2014**, 20, 1881-90	8.4	93
53	Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. *Hepatology*, **2013**, 57, 2458-68	11.2	183
52	Generation and homing of iPSC-derived hematopoietic cells in vivo. *Molecular Therapy*, **2013**, 21, 1292-3	11.7	5
51	Generation of glycosylphosphatidylinositol anchor protein-deficient blood cells from human induced pluripotent stem cells. *Stem Cells Translational Medicine*, **2013**, 2, 819-29	6.9	18
50	RUNX1a enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells. *Blood*, **2013**, 121, 2882-90	2.2	96
49	Response: the role of RUNX1 isoforms in hematopoietic commitment of human pluripotent stem cells. *Blood*, **2013**, 121, 5252-3	2.2	
48	Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. *Cell Stem Cell*, **2012**, 10, 337-44	18	202

47	Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression. *Nature Protocols*, **2012**, 7, 2013-21	18.8	123
46	Promise and challenges of human iPSC-based hematologic disease modeling and treatment. *International Journal of Hematology*, **2012**, 95, 601-9	2.3	13
45	The phenotype of a germline mutation in PIGA: the gene somatically mutated in paroxysmal nocturnal hemoglobinuria. *American Journal of Human Genetics*, **2012**, 90, 295-300	11	124
44	Efficient derivation and genetic modifications of human pluripotent stem cells on engineered human feeder cell lines. *Stem Cells and Development*, **2012**, 21, 2298-311	4.4	28
43	Extensive Ex Vivo Expansion of Functional Human Erythroid Precursor Cells From Reprogrammed Post-Natal Blood Mononuclear Cells by Defined Factors. *Blood*, **2012**, 120, 975-975	2.2	
42	Molecular Imaging and Stem Cell Research. *Molecular Imaging*, **2011**, 10, 7290.2010.00046	3.7	13
41	Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. *Blood*, **2011**, 117, 4773-7	2.2	135
40	Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. *Blood*, **2011**, 118, 1801-5	2.2	73
39	Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. *Cell Research*, **2011**, 21, 518-29	24.7	363
38	Hematopoietic cells as sources for patient-specific iPSCs and disease modeling. *Cell Cycle*, **2011**, 10, 2840-4	4.7	9
37	Liver engraftment potential of hepatic cells derived from patient-specific induced pluripotent stem cells. *Cell Cycle*, **2011**, 10, 2423-7	4.7	51
36	Distinct Induced Pluripotent Stem Cell Clones with Somatic Mutations Prepared From PV Patients. *Blood*, **2011**, 118, 2826-2826	2.2	
35	Molecular imaging and stem cell research. *Molecular Imaging*, **2011**, 10, 111-22	3.7	13
34	Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types. *Regenerative Medicine*, **2010**, 5, 521-30	2.5	9
33	An improved method for generating and identifying human induced pluripotent stem cells. *Methods in Molecular Biology*, **2010**, 636, 191-205	1.4	16
32	Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. *Hepatology*, **2010**, 51, 1810-9	11.2	195
31	Reply:. *Hepatology*, **2010**, 52, 1169-1170	11.2	3
30	Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. *Stem Cells*, **2010**, 28, 713-20	5.8	355

29	Human IPS Cells Generated From Adult Peripheral Blood Cells and Purified CD34+ Cells by a Non-Integrating Plasmid.. *Blood*, **2010**, 116, 1589-1589	2.2	1
28	In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). *Cancer Immunology, Immunotherapy*, **2009**, 58, 209-20	7.4	31
27	Serial imaging of human embryonic stem-cell engraftment and teratoma formation in live mouse models. *Cell Research*, **2009**, 19, 370-9	24.7	43
26	Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. *Cell Stem Cell*, **2009**, 5, 97-110	18	454
25	Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. *Blood*, **2009**, 114, 5473-80	2.2	314
24	Lentiviral gene transduction of mouse and human stem cells. *Methods in Molecular Biology*, **2008**, 430, 243-53	1.4	30
23	Trophoblast differentiation defect in human embryonic stem cells lacking PIG-A and GPI-anchored cell-surface proteins. *Cell Stem Cell*, **2008**, 2, 345-55	18	44
22	Notch signaling activation in human embryonic stem cells is required for embryonic, but not trophoblastic, lineage commitment. *Cell Stem Cell*, **2008**, 2, 461-71	18	87
21	The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies?. *Cancer Research*, **2008**, 68, 10121-7	10.1	82
20	In vivo commitment and functional tissue regeneration using human embryonic stem cell-derived mesenchymal cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 20641-6	11.5	223
19	Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. *Stem Cells*, **2008**, 26, 1998-2005	5.8	235
18	The HMGA1a-STAT3 axis: an Achilles Heel for Hematopoietic Malignancies Overexpressing HMGA1a?. *Blood*, **2008**, 112, 3810-3810	2.2	0
17	Efficient Production of Human Hematopoietic Progenitors from Human Pluripotent Stem Cells Using Chemically Defined Media without Serum or Feeder Cells. *Blood*, **2008**, 112, 2463-2463	2.2	
16	Inducible and reversible transgene expression in human stem cells after efficient and stable gene transfer. *Stem Cells*, **2007**, 25, 779-89	5.8	55
15	How Reproducible Is Bioluminescent Imaging of Tumor Cell Growth? Single Time Point versus the Dynamic Measurement Approach. *Molecular Imaging*, **2007**, 6, 7290.2007.00031	3.7	17
14	Promoting human embryonic stem cell renewal or differentiation by modulating Wnt signal and culture conditions. *Cell Research*, **2007**, 17, 62-72	24.7	77
13	FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. *British Journal of Haematology*, **2007**, 137, 64-75	4.5	30
12	Developmental Potentials of Human Embryonic Stem Cells Lacking PIG-A and GPI-Anchored Proteins.. *Blood*, **2006**, 108, 1314-1314	2.2	

11	Electrophysiological properties of pluripotent human and mouse embryonic stem cells. *Stem Cells*, **2005**, 23, 1526-34	5.8	76
10	Defining the role of Wnt/beta-catenin signaling in the survival, proliferation, and self-renewal of human embryonic stem cells. *Stem Cells*, **2005**, 23, 1489-501	5.8	277
9	Myocyte enhancer factor 2 mediates calcium-dependent transcription of the interleukin-2 gene in T lymphocytes: a calcium signaling module that is distinct from but collaborates with the nuclear factor of activated T cells (NFAT). *Journal of Biological Chemistry*, **2004**, 279, 14477-80	5.4	58
8	Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro. *Lancet, The*, **2004**, 364, 163-71	40	138
7	FLT3/ITD Expression Increases Expansion, Survival and Entry into Cell Cycle of Human Hematopoietic Stem Cells.. *Blood*, **2004**, 104, 484-484	2.2	
6	Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells. *Molecular Therapy*, **2003**, 7, 827-38	11.7	126
5	Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. *Human Gene Therapy*, **2003**, 14, 1089-105	4.8	43
4	Human adult marrow cells support prolonged expansion of human embryonic stem cells in culture. *Stem Cells*, **2003**, 21, 131-42	5.8	287
3	Making lentiviral vectors more powerful and universal. *Discovery Medicine*, **2003**, 3, 48-9	2.5	
2	Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. *Blood*, **2002**, 99, 399-408	2.2	122
1	Scalable Production of Human Erythrocytes from Induced Pluripotent Stem Cells		1